DE2504615C3 - Verfahren zur Herstellung eines Geles mit einem Gehalt an ß-Methason- 17-benzoat bzw. Fluocinolonacetonid und Neomycin - Google Patents
Verfahren zur Herstellung eines Geles mit einem Gehalt an ß-Methason- 17-benzoat bzw. Fluocinolonacetonid und NeomycinInfo
- Publication number
- DE2504615C3 DE2504615C3 DE19752504615 DE2504615A DE2504615C3 DE 2504615 C3 DE2504615 C3 DE 2504615C3 DE 19752504615 DE19752504615 DE 19752504615 DE 2504615 A DE2504615 A DE 2504615A DE 2504615 C3 DE2504615 C3 DE 2504615C3
- Authority
- DE
- Germany
- Prior art keywords
- neomycin
- steroid
- weight
- gel
- benzoate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229930193140 Neomycin Natural products 0.000 title claims description 12
- 229960004927 neomycin Drugs 0.000 title claims description 12
- 238000000034 method Methods 0.000 title claims description 8
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 title claims description 5
- 229960001347 fluocinolone acetonide Drugs 0.000 title claims description 4
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 229940050390 benzoate Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims description 19
- 150000003431 steroids Chemical class 0.000 claims description 17
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 claims description 13
- 239000000499 gel Substances 0.000 claims description 13
- 229940053050 neomycin sulfate Drugs 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 239000004599 antimicrobial Substances 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 claims description 2
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 230000002906 microbiologic effect Effects 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- -1 Hydroxypropylmethyl Chemical group 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 208000027765 speech disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46025474A | 1974-04-11 | 1974-04-11 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE2504615A1 DE2504615A1 (de) | 1975-10-16 |
| DE2504615B2 DE2504615B2 (de) | 1977-07-14 |
| DE2504615C3 true DE2504615C3 (de) | 1980-10-02 |
Family
ID=23827960
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19752504615 Expired DE2504615C3 (de) | 1974-04-11 | 1975-02-04 | Verfahren zur Herstellung eines Geles mit einem Gehalt an ß-Methason- 17-benzoat bzw. Fluocinolonacetonid und Neomycin |
| DE19752515594 Expired DE2515594C3 (de) | 1974-04-11 | 1975-04-10 | Verfahren zur Herstellung eines stabilen, topisch aktiven Geles |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19752515594 Expired DE2515594C3 (de) | 1974-04-11 | 1975-04-10 | Verfahren zur Herstellung eines stabilen, topisch aktiven Geles |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPS535729B2 (enExample) |
| AU (1) | AU7776275A (enExample) |
| CA (1) | CA1049409A (enExample) |
| DE (2) | DE2504615C3 (enExample) |
| DK (1) | DK143537C (enExample) |
| FR (1) | FR2267107B1 (enExample) |
| GB (1) | GB1455552A (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59501159A (ja) * | 1982-06-24 | 1984-07-05 | スミス、ロバ−ト・アラン | 薬用ゲル組成物 |
| US4489070A (en) * | 1983-05-13 | 1984-12-18 | Schering Corporation | Betamethasone dipropionate cream |
| DE3333240A1 (de) * | 1983-09-12 | 1985-03-28 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mittel zur transdermalen applikation von arzneimittelwirkstoffen |
| AU592065B2 (en) * | 1984-10-09 | 1990-01-04 | Dow Chemical Company, The | Sustained release dosage form based on highly plasticized cellulose ether gels |
| FR2588189B1 (fr) * | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| DE3614095A1 (de) * | 1986-04-25 | 1987-10-29 | Goedecke Ag | Oxyalkylcellulose enthaltende gelzubereitung |
| ES2078256T3 (es) * | 1990-04-05 | 1995-12-16 | Knoll Ag | Formula farmaceutica para uso topico que contiene diclofenaco sodico. |
| WO2002022139A1 (en) * | 2000-09-14 | 2002-03-21 | Robert Theiler | Intraarticular agent for the treatment of osteoarthritis |
| ES2391721T3 (es) * | 2010-03-01 | 2012-11-29 | Laboratorios Salvat, S.A. | Disoluciones acuosas transparentes de acetónido de fluocinolona para el tratamiento de la infamación de oído |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1017746B (de) * | 1954-02-09 | 1957-10-17 | Upjohn Co | Verfahren zur Herstellung frei fliessender, nicht absetzender therapeutisch wirksamer Suspensionen |
| US3485915A (en) * | 1966-04-22 | 1969-12-23 | Revlon | Thickened hydroxypropyl cellulose compositions |
| DE2015300A1 (de) * | 1969-04-01 | 1970-10-29 | Syntex Corp., Panania;PM | örtliche, entzündungshemmende Präparate und Verfahren zu ihrer Verwendung |
| DK135267A (enExample) * | 1971-02-25 |
-
1975
- 1975-01-30 AU AU77762/75A patent/AU7776275A/en not_active Expired
- 1975-02-04 DE DE19752504615 patent/DE2504615C3/de not_active Expired
- 1975-03-20 JP JP3426675A patent/JPS535729B2/ja not_active Expired
- 1975-03-21 GB GB955575A patent/GB1455552A/en not_active Expired
- 1975-04-07 FR FR7510763A patent/FR2267107B1/fr not_active Expired
- 1975-04-07 DK DK147575A patent/DK143537C/da not_active IP Right Cessation
- 1975-04-10 DE DE19752515594 patent/DE2515594C3/de not_active Expired
- 1975-04-10 CA CA224,302A patent/CA1049409A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR2267107A1 (enExample) | 1975-11-07 |
| AU7776275A (en) | 1976-08-05 |
| JPS50132122A (enExample) | 1975-10-20 |
| CA1049409A (en) | 1979-02-27 |
| DK147575A (enExample) | 1975-10-12 |
| JPS535729B2 (enExample) | 1978-03-01 |
| DE2515594B2 (de) | 1978-12-07 |
| DK143537B (da) | 1981-09-07 |
| DE2504615A1 (de) | 1975-10-16 |
| DK143537C (da) | 1982-02-01 |
| FR2267107B1 (enExample) | 1978-07-28 |
| GB1455552A (en) | 1976-11-17 |
| DE2504615B2 (de) | 1977-07-14 |
| DE2515594C3 (de) | 1982-06-03 |
| DE2515594A1 (de) | 1975-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3783683T2 (de) | Hautpenetration verbessernde zusammensetzungen. | |
| DE2827018C2 (enExample) | ||
| DE3033893A1 (de) | Therapeutische triaethylentetramin enthaltende zusammensetzung zur lokalen behandlung von hautzustaenden und ihre verwendung | |
| DE2802924C2 (de) | Arzneimittel zur Behandlung von Akne | |
| DE2747631C3 (de) | Salbe | |
| DE2615140C2 (de) | Mittel mit einem pharmazeutischen Träger auf Basis von Pyrrolidonverbindungen und Verfahren zu dessen Herstellung | |
| EP0773022B1 (de) | Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensäure | |
| DE69822295T2 (de) | Verwendung von misoprostol und/oder misoprostolsäure zur behandlung von erektionsstörungen | |
| DE3781182T2 (de) | Tamoxifen zur topischen verwendung. | |
| DE3587321T2 (de) | Pharmazeutische zusammensetzungen mit gehalt an einer organo-germaniumverbindung und ihre anwendung. | |
| DE10197266T5 (de) | Verfahren zur örtlichen Betäubung und Schmerzstillung | |
| DE69320968T2 (de) | Neue bioaktive zusammensetzungen, ihre herstellung und verwendung | |
| DE69224071T2 (de) | Chinolan-antibiotika und polystyrolsulfonat enthaltende zusammensetzungen | |
| DE2504615C3 (de) | Verfahren zur Herstellung eines Geles mit einem Gehalt an ß-Methason- 17-benzoat bzw. Fluocinolonacetonid und Neomycin | |
| DE2610020A1 (de) | Pharmazeutische zusammensetzung | |
| DE3875346T2 (de) | Zusammensetzungen, die mit 1-oxo- oder thiokohlenwassserstoff substituierte azacycloalkane enthalten. | |
| DE2425281A1 (de) | Pharmazeutische zusammensetzung | |
| DE2557431C2 (de) | Topisch anwendbares antimikrobielles Präparat | |
| DE3601923A1 (de) | Nasal applizierbares arzneimittel, verfahren zu seiner herstellung und seine verwendung | |
| DE3882042T2 (de) | Antiallergische augentropfen. | |
| DE19541919A1 (de) | Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden | |
| DE3443242A1 (de) | Glycyrrhizin und einen wirkstoff enthaltendes arzneimittel | |
| DE2721014A1 (de) | Echinacea und milchsaeurederivate enthaltendes arzneimittel | |
| DE1282855B (de) | Kosmetisches Lichtschutzmittel | |
| DE2939778A1 (de) | P-tolyl-dijodmethyl-sulfon enthaltende pharmazeutische zusammensetzung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) | ||
| 8328 | Change in the person/name/address of the agent |
Free format text: HENKEL, G., DR.PHIL. FEILER, L., DR.RER.NAT. HAENZEL, W., DIPL.-ING., PAT.-ANW., 8000 MUENCHEN |
|
| 8339 | Ceased/non-payment of the annual fee |